Phase 3
Completed N=120
Efficacy and Safety of IQP-VV-102 in Weight Management
Source: ClinicalTrials.gov NCT01681069 ↗Enrolled (actual)
120
Serious AEs
0.0%
Results posted
Nov 2015
Primary outcomePrimary: Change in Body Weight at End of Study Compared to Baseline — 3.29; 0.83 kg
Summary
Subjects are randomized to either IQP-VV-102 or a matching placebo. Over 12 weeks, the subjects' body weight, body fat and safety parameters are monitored
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Body Weight at End of Study Compared to Baseline |
3.29; 0.83 | — |
| SECONDARY Change in Waist Circumference (in cm) at End of Study From Baseline |
2.11; 0.81 | — |
| SECONDARY Change in Mean Body Fat at End of Study From Baseline |
2.14; 0.56 | — |
Eligibility Criteria
Inclusion Criteria
- Age 18 to 60 years
- 25 kg/m2 ≤ BMI ≤ 35 kg/m2
- Written informed consent
Exclusion Criteria
- Known sensitivity to sources of the active ingredients and excipients
- Pregnancy or nursing
- Inability to comply with study requirements, e.g. due to language difficulties
- Participation in another study during the last 30 days of the screening visit
Data sourced from ClinicalTrials.gov (NCT01681069). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.